Research news

An antibody treatment trialled at UCLH cuts the risk of developing symptomatic COVID-19 by 77%.

A national study involving UCLH has deepened understanding of the symptoms, signs and outcomes of patients with the novel condition vaccine-induced immune thrombocytopenia and thrombosis (VITT), associated with the Oxford/AstraZeneca vaccine.

A clinical trial of a new drug candidate for Alzheimer’s disease which has been developed at UCL in partnership with the pharmaceutical company Eisai has begun at UCLH with participants now being screened.

A major new consortium led by UCLH and UCL has been awarded £6.8 million by the National Institute of Health Research to conduct the largest clinical study of long COVID over the next two years.